OZEM vs. CANC ETF Comparison

Comparison of Roundhill GLP-1 & Weight Loss ETF (OZEM) to Tema Oncology ETF (CANC)
OZEM

Roundhill GLP-1 & Weight Loss ETF

OZEM Description

OZEM targets the global weight management industry. The fund invests in companies involved in the development of GLP-1 and other weight loss drugs. GLP-1 agonists seek to aid in weight management by lowering blood sugar levels, reducing appetite, and promoting fullness. The portfolio consists of firms with GLP-1 and weight loss drugs that have been approved by or are currently undergoing Phase I, Phase II, and/or Phase III clinical trials of the US Food & Drug Administration (FDA), or any applicable food and drug regulator for non-US companies. The portfolio is constructed using a proprietary methodology, which selects companies with high levels of thematic relevance based on research of each companys public filings and disclosures. In addition, eligible securities must meet minimum market-cap and liquidity requirements. The actively managed fund, although rebalances portfolio weighting on at least a quarterly basis, may have a heavy concentration on a few names.

Grade (RS Rating)

Last Trade

$26.27

Average Daily Volume

82,294

Number of Holdings *

7

* may have additional holdings in another (foreign) market
CANC

Tema Oncology ETF

CANC Description Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Grade (RS Rating)

Last Trade

$27.30

Average Daily Volume

17,838

Number of Holdings *

8

* may have additional holdings in another (foreign) market
Performance
Period OZEM CANC
30 Days 4.45% -0.54%
60 Days 6.27%
90 Days -0.64%
12 Months
1 Overlapping Holdings
Symbol Grade Weight in OZEM Weight in CANC Overlap
AMGN B 4.2% 3.37% 3.37%
Compare ETFs